View More View Less
  • 1 Debreceni Egyetem Általános Orvosi Kar, 4032 Debrecen, Nagyerdei krt. 98.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Absztrakt:

A myeloproliferativ neoplasmák 2016-ban megújult WHO diagnosztikus kritériumrendszere újradefiniálta a polycythaemia vera kritériumait, a diagnózis lépéseit, melyek között szerepel a molekuláris megközelítés mellett a cristabiopszia is. Megújultak a kockázatmérlegelés eszközei, beleértve az életkort, korábbi thrombotikus eseményt, a genetikai hátteret, a terápiás választ rövid távon, s a transzformációk szempontjából is. A JAK2 titer és annak csökkentésére irányuló törekvések egyre nagyobb figyelmet kapnak. Az alapterápiában használt phlebotomia- és aszpirinkombinált kezelés mellett a standard cytoreduktív kezelés a hydroxyurea volt és bizonyos esetekben, talán nagyobb részben az is maradt. Számos szempont alapján újabb alternatív terápiák kiválasztására van lehetőség és szükség. A közlemény a gyakorlati ellátás szempontjai alapjából elemzi a diagnosztikus kritériumok dilemmáit, elemzi a molekuláris diagnosztikát, a követéses vizsgálatok fontosságát, s igyekszik a klinikai gyakorlat szempontjai alapján útmutatást nyújtani az innovatív kezelési módok indikációja, választása és alkalmazása tekintetében is.

  • 1

    Dombi P, Illés Á, Demeter J, et al. Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients. [Philadelphia-negatív krónikus Myeloproliferativ Neoplasia Magyarországi Regiszter. Polycythaemia verás betegeink adatainak elemzése.] Orv Hetil. 2017; 158: 901–909. [Hungarian]

  • 2

    Dombi P, Illés Á, Demeter J, et al. An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients. [Philadelphia-negatív krónikus Myeloproliferativ Neoplasia Magyarországi Regiszter. Essentialis thrombocythaemiás betegeink adatainak elemzése.] Orv Hetil. 2017; 158: 111–116. [Hungarian]

  • 3

    Dombi P, Illés Á, Demeter J, et al. Development of the registry for Philadelphia-negative chronic myeloproliferative neoplasia in Hungary. [Philadelphia-negatív krónikus myeloproliferativ neoplasia regiszter magyarországi létrehozása.] Orv Hetil. 2016; 157: 98–103. [Hungarian]

  • 4

    Marton I, Simon Zs, Borbényi Z. Diagnosis and treatment of polycythaemia vera: state of the art. [Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében.] Orv Hetil. 2016; 157: 1743–1751. [Hungarian]

  • 5

    Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8: 15.

  • 6

    Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391–2405.

  • 7

    Chittiboina P, Lonser RR. Von Hippel–Lindau disease. Handb Clin Neurol. 2015; 132: 139–156.

  • 8

    Lenglet M, Robriquet F, Schwarz K, et al. New lessons from an old gene: complex splicing and a novel cryptic exon in VHL gene cause erythrocytosis and VHL disease. Blood. 2018; 132: 469–483.

  • 9

    Gordeuk VR. Chuvash polycythaemia: diagnosis and management. Clin Adv Hematol Oncol. 2011; 9: 929–930.

  • 10

    Toyoda H, Hirayama J, Sugimoto Y, et al. Polycythaemia and paraganglioma with a novel somatic HIF2A mutation in a male. Pediatrics. 2014; 133: 1787–1791.

  • 11

    Lenglet M, Robriquet F, Schwarz K, et al. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel–Lindau disease. Blood. 2018; 132: 469–483.

  • 12

    Charache S. A manifestation of abnormal hemoglobins of man: altered oxygen affinity. Hemoglobin Chesapeake: from the clinic to the laboratory, and back again. Ann N Y Acad Sci. 1974; 241: 449–455.

  • 13

    Yasar SJ, Ravn Berg VI, Ahmad A, et al. Hemoglobin Titusville: a rare low oxygen affinity hemoglobinopathy. Clin Case Rep. 2017; 5: 1011–1012.

  • 14

    Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009; 23: 834–844.

  • 15

    Rumi E, Passamonti F, Pagano L, et al. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. J Intern Med. 2009; 265: 266–274.

  • 16

    Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011; 2: 21–32.

  • 17

    Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythaemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574–1579.

  • 18

    Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythaemia vera exerts an impact on clinical outcome. Blood 2012; 119: 2239–2241.

  • 19

    Rumi E, Sant’Antonio E, Boveri E, et al. Diagnosis and management of prefibrotic myelofibrosis. Expert Rev Hematol. 2018; 11: 537–545.

  • 20

    van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol. 1996; 93: 962–965.

  • 21

    Lancellotti S, Dragani A, Ranalli P, et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost. 2015; 13: 1226–1237.

  • 22

    Reményi G, Szász R, Debreceni I et al. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment. Platelets 2013; 24: 486–492.

  • 23

    Lippi G, Franchini M, Salvagno GL, et al. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. J Thromb Thrombolysis 2008; 26: 150–153.

  • 24

    Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–6785.

  • 25

    Tefferi A. Polycythaemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88: 507–516.

  • 26

    Falchi L, Bose P, Newberry KJ, et al. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol. 2017; 176: 352–364.

  • 27

    Cervera JS, Mena-Durán AV, Piqueras CS. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost. 2005; 93: 383–384.

  • 28

    Tefferi A, Barbui T. Polycythaemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015; 90: 162–173. Review. Erratum in: Am J Hematol. 2015.

  • 29

    Tefferi A, Vannucchi AM, Barbui T. Polycythaemia vera treatment algorithm 2018. Blood Cancer J. 2018; 8: 3.

  • 30

    Vannucchi AM, Guglielmelli P, Tefferi A. Polycythaemia vera and essential thrombocythemia: algorithmic approach. Curr Opin Hematol. 2018; 25: 112–119.

  • 31

    Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015; 29: 215–221.

  • 32

    Michiels JJ. Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. World J Crit Care Med. 2015; 4: 230–239.

  • 33

    Squizzato A, Romualdi E, Passamonti F, et al. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2013; (4): CD006503.

  • 34

    Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythaemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol. 2016; 77: 1125–1142.

  • 35

    Alimam S, Harrison C. Experience with ruxolitinib in the treatment of polycythaemia vera. Ther Adv Hematol. 2017; 8: 139–151. Erratum in: Ther Adv Hematol. 2017; 8: 273.

  • 36

    Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythaemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5: 366.

  • 37

    Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythaemia vera, and myelofibrosis. Blood 2014; 124: 2507–2513.

  • 38

    Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythaemia vera. Blood 2015; 126: 1762–1769.

  • 39

    Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythaemia vera. N Engl J Med. 2015; 372: 426–435.

  • 40

    Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythaemia vera enrolled in the RESPONSE study. Ann Hematol. 2017; 96: 1113–1120.

  • 41

    Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythaemia vera. N Engl J Med. 2004; 350: 114–124.

  • 42

    Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythaemia (ECLAP); low-dose aspirin in polycythemia (ECLAP). Pathol Biol. (Paris) 2004; 52: 285–288.

  • 43

    Karabinos I, Koulouris S, Kranidis A, et al. Neutrophil count on admission predicts major in-hospital events in patients with a non-ST-segment elevation acute coronary syndrome. Clin Cardiol. 2009; 32: 561–568.

  • 44

    Osmancik P, Paulu P, Tousek P, et al. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. J Throm Thrombolysis 2012; 33: 349–354.

  • 45

    Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015; 126: 560–561.

  • 46

    Kremyanskaya M, Mascarenhas J, Hoffman R. Anagrelide hydrochloride and ruxolitinib for treatment of polycythaemia vera. Expert Opin Pharmacother. 2015; 16: 1185–1194.

  • 47

    Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythaemia vera and essential thrombocythemia. Haematologica 2008; 93: 331–335.

  • 48

    MH Steinberg, WF McCarthy, O Castro, et al. Follow-up the risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010; 85: 403–408.

  • 49

    Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia 2018; 32: 2203–22010.

  • 50

    Kaplan ME, Mack K, Goldberg JD, et al. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol. 1986; 23: 167–171.

  • 51

    Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythaemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006; 32: 417–421.

  • 52

    Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythaemia vera: an international study. Leukemia 2013; 27:1874–1881.

  • 53

    Passamonti F. How I treat polycythaemia vera. Blood 2012; 120: 275–284.

  • 54

    Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018; 97: 1591–1600.

  • 55

    Gángó A, Mózes R, Boha Z, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res. 2018; 65: 42–48.

  • 56

    Bjørn ME, de Stricker K, Kjær L, et al. Rapid clearance of JAK2 V617F allele burden in patient with advanced polycythaemia vera (PV) during combination therapy with ruxolitinib and peg-interferon alpha-2a. Blood 2013; 122: 5241.

  • 57

    Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythaemia vera. Ann Hematol. 2015; 94: 901–910.

  • 58

    Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Phˈ-negative MPN. Am J Hematol. 2012; 87: 552–554.

  • 59

    Hatalova A, Schwarz J, Gotic M, et al. Recommendations for the diagnosis and treatment of patients with polycythaemia vera. Eur J Haematol. 2018 Jul 30. [Epub ahead of print].

    • Crossref
    • Export Citation
  • 60

    Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014; 12: e268.

  • 61

    Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011; 365: 1455–1457.